Combination of Tranylcypromine and Mirtazapine in Difficult-to-Treat Depression
| Autor: | Erhan Kavakbasi, Bernhard T. Baune |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry Tranylcypromine Mirtazapine medicine.disease Serotonin syndrome Neuroleptic malignant syndrome Psychiatry and Mental health Internal medicine medicine Antidepressant Pharmacology (medical) Amitriptyline Aripiprazole medicine.symptom business Depression (differential diagnoses) medicine.drug |
| Zdroj: | Journal of Clinical Psychopharmacology. 41:585-588 |
| ISSN: | 1533-712X 0271-0749 |
| DOI: | 10.1097/jcp.0000000000001452 |
| Popis: | Background About one third of depression patients do not respond to the first antidepressant trial. Difficult-to-treat depression was suggested to characterize the often chronic and severe course of disease. Previous data indicate that tranylcypromine is effective in case of treatment-refractory depression. Many antidepressants are contraindicated in combination with tranylcypromine and other monoamine-oxidase inhibitors because of the risk of serotonin syndrome. The combination of tranylcypromine and amitriptyline was reported to be efficacious and safe in patients with electroconvulsive therapy-resistant major depression. Methods In this retrospective chart review, we report a series of 3 cases, in which patients with electroconvulsive therapy-resistant depression were treated with the combination of tranylcypromine and mirtazapine. There are no published clinical data on this combination yet. Disease severity and treatment response were retrospectively assessed with the Clinical Global Impression-Severity and Improvement Scales. Results All 3 patients had severe difficult-to-treat depression with chronic course of disease and several times of inpatient treatment without achieving remission. The combination treatment was tolerated well, although the patients had somatic comorbidities. One patient developed mild and self-limiting neuroleptic malignant syndrome in the long-term course after dose increase of concomitant aripiprazole. All 3 patients showed either much or very much improvement. Conclusions Under tight clinical controls in inpatient setting and after exhausting of alternatives, the combination of tranylcypromine and mirtazapine could be considered in patients, who do not achieve adequate improvement through common treatment options recommended in the guidelines. The combination has to be ceased, if symptoms of possible serotonin syndrome occur. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|